View all veterinary jobs
VetNurse.co.uk publishes a curated feed of veterinary nursing news for registered veterinary nurses (RVNs), students (SVNs) and veterinary nursing assistants, with a primary focus on the UK profession.
We select stories based on their practical relevance, clinical interest or professional significance — filtering out noise so busy veterinary nurses can stay informed quickly.
Our coverage includes:
We report across all areas of practice, including companion animal, referral and specialist settings, with a focus on issues affecting veterinary nurses in clinical and professional roles.
Our editorial approach is deliberately selective and concise. We prioritise clarity and relevance over volume, aiming to make each story worth your time.
You can follow VetNurse news by subscribing to the daily, weekly or monthly email digest, or via our channels on Facebook and LinkedIn.
Henry Schein, Inc. has announced the acquisition of Veterinary Instrumentation, the supplier of surgical instruments and implants to veterinary surgeons in the United Kingdom.
Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein said: "We are delighted to welcome this highly regarded company to the Henry Schein family, and very pleased that founder John Lapish and Managing Director Steve Fletcher will continue to drive the business forward.
"The success of Veterinary Instrumentation closely parallels the cornerstones of Henry Schein, including a deep understanding of customer needs, innovative solutions, superior product quality and customer service, and a trusted advisory relationship with our customers. Reinforcing our existing animal health business in the U.K., we look forward to strengthening our relationship with veterinary customers in this region, and bringing the Veterinary Instrumentation product portfolio of high-quality surgical specialties to a growing number of veterinarians across Europe, the United States and Australasia."
Veterinary Instrumentation was founded by John Lapish in 1986 in Sheffield, England, where the business and distribution operations are currently conducted from a single facility. Working as a small animal orthopaedic surgeon in the late 1970s, Mr. Lapish began designing and developing a range of instruments specifically for veterinary surgery, initially for his own use. As requests for these products increased, the market need became clear and Veterinary Instrumentation was formed, in particular to meet the needs of orthopaedic surgeons focused on small animals.
Mr Lapish said: "We look forward to contributing to the continued growth and success of a leading supplier of companion animal health products and services in the United Kingdom and to becoming part of a global leader in the distribution of health care products and services.
"The expertise that we bring in the area of veterinary surgical instruments will complement Henry Schein's broad offering, and our customers will benefit greatly from the global resources of a company that has quickly become an animal health care product and service leader on three continents."
With approximately 60 percent of sales in the U.K., and the balance split fairly evenly between Europe and the rest of the world, Veterinary Instrumentation has 20 employees, including a team of eight Veterinary Technicians who advise customers on the most appropriate procedures and instrumentation.
Veterinary Instrumentation sales for the 12 months ended September 30, 2011 were approximately £6.7 million ($10.8 million). Financial terms of the transaction were not disclosed.
The company says many in the profession are unaware of what PCA's can do, which means they're often not used to their full potential and instead wind up doing the cleaning.
The CVS PCA Hub is intended to help staff develop all of the attributes required of a great veterinary PCA, with courses covering theatre practice, dispensary, lab skills, consulting skills, neonatal care and inpatient care.
Training ranges from short bite size learning to an in-depth Level 2 Certificate in Veterinary Care Support Apprenticeship.
The PCA Hub has been made available to all CVS staff in both clinical and non clinical roles, and the company says many of the courses are free or trainees can use their CPD allowance.
Rob Kelly, Head of Clinical Veterinary Education at CVS, said: “We want our Patient Care Assistants to have better job satisfaction and to make their day-to-day jobs more rewarding.
"We also want practices to understand the skills they have and to use them to their full potential, whilst freeing up other clinical staff to do other jobs.
“So this new hub for the first time provides all of the training, resources and support required by our Patient Care Assistants - in a one-stop-shop.
"The courses have been specifically designed to provide our PCAs with their own continuous professional development.
"A lot of PCAs will also go on to become student vet nurses, so giving them this foundation will hugely help them with their future studies.”
cvs-knowledgehub.com
Dr David Reese, Director of VetCT Australia and a Diplomate in veterinary diagnostic imaging will present: "Leveraging CT to Diagnose and Manage Unusual Pets", followed by a Q&A session.
David said: “This webinar is a fantastic opportunity to share knowledge about optimising imaging for exotic animals to reach an accurate diagnosis.
"The field of exotics imaging has rapidly advanced in recent years.
"With the increasing use of CT alongside traditional radiography, we can see so much more and provide high-quality reports to our client practices that empower them to give great care.
"We’re excited to support Exotic Vet Support with this CPD programme.”
Attendees will also receive an exclusive discount for the Exotic Vet Support Asia-Pacific (EVSAP) Conference 1st-2nd March 2024 in Sydney.
A recording of the webinar will be available after the live session, and for attendees of the EVSAP Conference.
Register here: https://vetct.zoom.us/webinar/register/WN_i_8KgMbPSeGZ-i7AbxaDqw#/registration
Gordon Hockey has been appointed Acting Registrar at the Royal College of Veterinary Surgeons.
He succeeds Jane Hern, who had been Registrar for 15 years before deciding to move on to pursue other interests.
Gordon, who is a qualified pharmacist and barrister, has been at the College for the last 13 years as Head of the Professional Conduct Department and Assistant Registrar.
Meanwhile, the College says it is giving consideration to the future scope of the Registrar and Secretary's roles, as the Officer team begins the recruitment process.
Eleanor Ferguson has taken over as Acting Head of the Professional Conduct Department.
The new Chestergates ophthalmology service will offer a wide range of treatments for eye conditions, including: cryotherapy, corrective lid surgery, rhytidectomy, nasal fold ablation, cherry eye and scrolled cartilage, keratotomy, keratectomy, pedicle conjunctival graft, corneo-conjunctival transposition, bioimplants for corneal reconstruction, glaucoma diagnosis and monitoring, management of dry eye (KCS) and neurological dry eye, retro-bulbar disease investigation and treatment, cataract assessment, and intracapsular lens extraction.
The service will be led by Chestergates Advanced Practitioner in Ophthalmology, Endika Garcia MRCVS DVM PGCertSAOphthal.
Endika graduated in 2016 from the University of Valencia, completed a rotating internship, then worked for a few years in different hospitals in Spain, before moving to the UK, enrolling on the BSAVA Certificate in Small Animal Ophthalmology and being awarded Advanced Practitioner status.
Endika will be supported by a 25 strong specialist nursing team, four nurse students, one lab technician, two sterile technicians and a team of receptionists and support colleagues.
Consultations and surgical procedures will be offered at Chestergates Veterinary Specialists on Mondays and Thursdays between 8am and 5pm.
https://chestergates.org.uk/referral-services
The University of Bristol's Langford Veterinary Services (LVS) has announced the completion of its new clinical facilities.
The first phase of the £13 million development includes a new small animal surgery building, comprising five theatres, an ICU, a dedicated anaesthesia induction and recovery and an imaging suite.
The imaging suite comprises a 16-slice CT scanner, for small animals and horses, conventional digital radiography with a DR system, a high-resolution fluoroscopy, diagnostic ultrasound, echocardiography, scintigraphy and a high resolution 1.5 tesla MRI scanner available seven days a week.
Lynne Hill, Chief Executive of LVS, said: "The new facility provides state-of-the art diagnostic imaging facilities at all times, to help the animals under our care."
LVS highlights the case of Gainsborough, an eight-year-old Irish draught gelding, to illustrate the benefits of its new facilities. The horse, used for jumping and endurance, was initially presented to the Equine Hospital in October 2010, with clinical signs including nasal airflow obstruction and discharge, which was limiting his athletic capabilities.
Using videoendoscopy and radiography, a space-occupying mass was diagnosed in the paranasal sinuses impinging into the nasal cavity. With the horse conscious, but sedated, using regional local anaesthetic nerve blocks, the bulk of the mass was removed and he returned to work. However, the owner reported a recurrence of the clinical signs and he was returned to the clinic for reassessment.
The new imaging suite, only one of a few such units in the UK, has been adapted to enable the imaging of a horse's head while conscious using a frictionless air plinth. The adaptation allows detailed imaging of both bone and soft tissue structures within a horse's head, without requiring a general anaesthetic.
Using the new imaging suite, Gainsborough's CT examination revealed a portion of the mass, which had been inaccessible to the previous keyhole surgery, had expanded into the nasal cavity. The detail of the images enabled careful planning of a second operation that facilitated removal of the large remnant of the mass, which appeared to be benign, with minimal collateral trauma.
In addition to imaging the heads of conscious horses, dogs and cats are able to undergo complete body scans using the same unit while anaesthetised. As well as enabling detection and diagnosis of lesions without invasive or painful tests at an earlier stage, the unit will facilitate operative planning and add to the body of knowledge of disease pathogenesis.
For more information about LVS, visit: http://www.langfordvets.co.uk/
Norbrook Laboratories has launched powder and paste versions of Noroquin - its glucosamine-based supplement range - for horses.
Noroquin contains the active ingredients glucosamine, chondrotin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine, designed to maintain healthy cartilage, promote joint management and keep horses mobile.
Michelle Jones, Brand Manager at Norbrook said: "In recent years, horses are increasingly competing longer which means maintaining the longevity of the horse is vitally important for long term success. 60% of lameness is related to osteoarthritis and is regarded as the major cause of disability in the athletic horse.
"With increasing reliability on nutritional supplements and concerns from horse owners about their aging horse, our Noroquin for Horses range can be offered as alternative to traditional pain management products indicated for musculoskeletal ailments or alongside them as a completely safe addition to a joint management programme."
Michelle added: "The Noroquin paste for horses is a highly palatable apple flavored paste that can be fed directly to the horse as a tasty treat and offers an alternative to traditional methods while the Noroquin powder for Horses is a highly palatable powder that can be mixed with food. The product is available in handy single-use sachets for accurate dosing and waterproof 1kg tubs."
Noroquin Powder and Paste for Horses joins the newly launched tasty tablets for dogs and cats and powder for cats in the Noroquin range. It is available from wholesalers.
Vetoquinol has announced that the 50g pack size of Ipakitine will shortly be replaced by a 60g pot.
The company says this will provide the convenience of a 30 day supply for a 5kg cat or dog who is on 1g/5kg bodyweight twice a day (one level scoop twice a day).
The 60g pot will be available from the end of December. Also at this time, the existing 150g size pot will be replaced by a 180g pot.
The new packaging is more eye-catching, easier to read and gives more description. A 300g pot will also be available in February 2012. Pricing will be in-line with increase in pack size, so proportionally a 20% increase for 20% more product.
Ipakitine is a phosphate binder formulated specifically for veterinary use. It is designed for both cats and dogs and is available as a tasteless powder formulation for easy administration with food.
Norbrook Laboratories has launched NoroQuin, a nutritional glucosamine-based supplement which the company claims will help maintain healthy cartilage and joint fluids in cats, dogs and horses.
The NoroQuin range has six active ingredients including glucosamine, chondroitin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine which combine to maintain glycosaminoglycans (GAGs) levels in joints and, according to Norbrook, ease and reduce the onset of joint damage and cartilage degeneration.
Michelle Jones, Norbrook Brand Manager, said: "Our new NoroQuin range is an exciting new development to our joint-management range.
"NoroQuin offers more ingredients than the competition with 6 active ingredients working together to help improve mobility. The main ingredient, glucosamine stimulates natural repair and prevents cartilage degeneration and thinning while it is widely considered that glucosamine and chondroitin sulphate have anti-inflammatory properties, making Noroquin ideal for assisting with pain management. The addition of manganese sulphate helps stimulate natural cartilage repair."
NoroQuin is available in a range of meat flavoured tablet sizes that have been formulated to treat all dogs from growing puppies to the largest dogs. For cats, the range is available in a tablet form or as a powder which can be added to a cat's food.
NoroQuin for dogs and cats is available to order from wholesalers now.
Animalcare has been found in breach of Clause 18.2 of the NOAH Code of Practice for offering and supplying infusion pumps/equipment in exchange for veterinary practices entering into written contracts for the purchase of a range of its products, including the POM-V Benazecare.
The value of the equipment offered by Animalcare equated with a discount agreed with the veterinary practice, and was applied as medicinal products were purchased. The equipment was supplied on the signing of a contract. The terms of the contract required a particular quantity of medicinal products to be purchased, and if the veterinary practice failed to meet that requirement, there was a liability to pay a pro-rata element of the equipment purchase price.
The Code of Practice Committee was of the view that a piece of equipment was neither 'price' nor 'product' within the meaning of Clause 18.2 of the Code of Practice; and as such amounted to a gift being offered in relation to the sale; or purchase; or prescription of animal medicine. The Committee took into account that Guidance Note 4, paragraph 7, states that the word "gift" includes any pecuniary advantage being offered, with the exception of price or product itself.
To comply with Code of Practice Clause 18.2, the offer or inducement based on price had to be one of cash as rebated discount. If then there were facilities to enable the veterinary practice to use that rebated discount to purchase the equipment from the supplier, that might be acceptable, but there was a necessity for cash as rebated discount to be provided in the first instance.
Full details of the Committee's rulings are available on the NOAH website at www.noah.co.uk/code.
Avid has released a new version of it's microchip registration system, which offers a significantly enhanced statistical analysis of the microchipping done at your practice.
The new MicroChip Plus section of the site is specifically for implanters, and contains the following:
Avid says the registration system, which has built-in postcode software, can now re-use more registration details, so that registering a complete litter will take less time. This is especially important when microchips are being registered for or by breeders.
Denise Chaloner, Manager at Avid said: “Avid MicroChip Plus gives our customers more control of how they manage pet microchipping within their organisation. Listening to feedback has inspired Avid to develop a more tailor-made and efficient system for the end user, also enabling the generation of reports, statistics and targets”.
Customers with supporting practice management systems may register microchips directly from their software using VetXML and VetEnvoy.
For more information contact Avid on freephone 0800 652 7 977 or email sales@avidplc.com
Dunlops has changed its name to Henry Schein Animal Health.
David Hinton, Managing Director said: "As we change our name to Henry Schein Animal Health, we also reaffirm our company's strong commitment to offer a comprehensive array of products and services to help animal health practitioners in the United Kingdom operate more efficient and successful practices, and provide the best quality patient care.
"We have a new name, but we have the same strong team, the same values, and the same dedication to providing excellent service to our customers."
Henry Schein Animal Health’s expanded offerings include VetLink and Thrive. VetLink is a new e-commerce web site system that enables veterinary surgeons to access the growing internet sector, allowing you to sell anything from pet prescriptions to accessories online, to be delivered to your customers’ homes by Henry Schein Animal Health. Thrive is a new veterinary business analysis service that integrates with practice management software to use a Key Performance Indicator based approach that provides insight into a your practice and identifies areas where you can enhance your business.
The BSAVA has announced a partnership with the University of Liverpool to develop a national UK disease surveillance network for companion animals.
Originally established in 2008, the Small Animal Veterinary Surveillance Network, SAVSNET, aimed to monitor the disease status of the UK small animal population (mainly dog, cat and rabbit). However, funding for the project came to an end in August 2011. At this point, BSAVA stepped in with support, as it believed that not only would the profession benefit from this source of information, but that it is in fact vital for the successful management of disease in small animals.
BSAVA President Andrew Ash said: "SAVSNET ticks all the boxes for BSAVA. High quality large scale epidemiological research helps us fulfil our obligations as a charity to public good, the information on disease surveillance gives us the information to treat animals better, and the research papers help us inform veterinary policy and education. This is an important scheme for both animal and human health."
Participation by diagnostic labs and practices is voluntary, and all data gained will be made anonymous before being reported. For more information, email savsnet@liverpool.ac.uk.
Veterinary surgeons and veterinary nurses will be able to try their hands at the Royal College of Veterinary Surgeons code-cracking competition at the London Vet Show at Olympia on 24-25 November.
At the RCVS breakfast session on the Friday morning (8.30, part of the Business Stream), President Dr Jerry Davies will unlock the secrets of the proposed new Codes of Professional Conduct for vets and VNs.
To promote this breakfast session, the RCVS is inviting visitors to come to its stand (J90) to solve photo enigmas, using clues provided to decipher a series of words that appear in the proposed new Codes. The winner will be in line to receive a pair of super sleuthing video glasses.
VNs who missed BVNA Congress can also get their hands on a 50th anniversary commemorative chocolate medallion by visiting the RCVS stand.
Coffee and pastries will be served at the morning session on Friday - there's no need to book, just turn up.
Bayer Animal Health has launched a next generation fluoroquinolone antimicrobial - Veraflox (pradofloxacin) - for the treatment of bacterial infections in cats and dogs.
Bayer Animal Health's marketing manager Dr Markus Edingloh said: "Veraflox, with its molecular compound pradofloxacin, developed exclusively for veterinary medicine, marks a major leap forward in veterinary antibiotic therapy and patient care.
"Veraflox has an enhanced spectrum of antimicrobial activity which encompasses Gram-positive and anaerobic bacteria. In addition, Veraflox has demonstrated high levels of bactericidal activity against target pathogens including activity against dormant bacteria typically found in chronic infections."
For cats, an oral suspension is available in which a fine-grained ion exchange agent binds to the antibiotic, apparently allowing it to pass the cat's taste buds undetected. Bayer says this innovation has been adopted specifically to ensure the product is palatable to cats, and help ensure owner compliance. The oral suspension comes with a syringe with both millilitre and gramme graduations, to help ensure accurate dosing.
Veraflox oral suspension is indicated for the treatment of upper respiratory tract infections, wound infections and abscesses. The 15mg tablet is also licensed in cats for treating upper respiratory tract infections.
Bayer says that in addition to its other indications, Veraflox is also very effective at combatting anaerobic bacteria that play a major role in aggressive bone destruction in canine periodontal disease, and it is the first fluoroquinolone to be licensed in dogs for the adjunctive treatment of severe infections of the gingiva and periodontal tissues.
In addition to its dental claim for dogs, Veraflox is also indicated for the treatment of wound infections, superficial and deep pyoderma, and acute urinary tract infections. It is given to dogs as a once-daily flavoured tablet.
Dr Edingloh added: "The unique chemistry and way in which Veraflox works gives it superior antibacterial activity compared with existing fluoroquinolones. In addition, during field studies, Veraflox was shown to be superior to other leading antibiotic products.
"Pradofloxacin has been proven to have a wide spectrum of activity, outstanding antibacterial activity, and an excellent safety margin. Its pharmacokinetic features ensure this active ingredient can rapidly get to the site of infection, at which it has a great impact on the pathogen population.
"One of the most common reasons for treatment failure where antibiotics are concerned is lack of owner compliance. The availability of Veraflox as an oral suspension with a graded syringe for cats, will enable more accurate dosing, far easier administration and so ensure higher cure rates.
"The launch of Veraflox is the first major advance in its class, since the introduction of Baytril, the first veterinary fluoroquinolone, over 20 years ago. Veraflox provides vets with more predictability, reliability and peace of mind, especially in difficult to treat infections."
For further information on Veraflox, please contact your Bayer representative or call 01635 563000.
B&W Equine Group has opened a brand new, state-of-the-art equine clinic at Breadstone in Gloucestershire.
The new facility opened on 1 October 2011. It cost over £2.2 million and is, according to the company, one Europe’s most advanced diagnostic and surgical centres.
B&W Equine Group was created in 2008, following a merger between Willesley Equine Clinic and Bushy Equine Vets. The 23 vet practice has four local equine clinics in Breadstone, Cardiff, Failand and Willesley.
The new clinic, located on a four acre site at Breadstone, close to the M4 and M5 intersections, provides state-of-the-art diagnostics and advanced laboratory facilities. It houses the only equine MRI scanner in Wales and the South West, as well as a CT scanner and scintigraphy unit. Orthopaedic and colic theatres, adult and neonatal intensive care suites and separate isolation units have all been custom-designed and are supported by five examination rooms and two knock down boxes.
Clinical and referral services are led by RCVS and European Recognised Specialists in surgery, orthopaedics, diagnostic imaging and internal medicine and include gynaecological management of breeding mares and pre-season disease screening. The on-site laboratory is one of only 30 in the UK to be certified by the HBLB to test for CEM and EVA.
Ian Camm, BVSc CertEP MRCVS, Group Director, said: “We are all extremely excited about the new clinic but our day-to-day first opinion work remains a top priority. For all our local clients it’s very much a case of business as usual but the fact that we have invested in the latest portable equipment, including video endoscopes, digital radiography and ultrasound scanners, means we can undertake more specialist work at client’s yards, as and when needed.”
For further information, visit www.bwequinevets.co.uk.
A research project funded by equine charity The Horse Trust has found that 40% of horses suffered a traumatic injury within the past year.
Only 13% of injuries occurred during ridden exercise, while 62% occurred while the horse was turned out in the field.
The research, which has been accepted for publication by the Equine Veterinary Journal, was carried out by Rosie Owen, who is currently working as The Horse Trust's Clinical Scholar in Equine Orthopaedics at the University of Liverpool.
Rosie said: "This Horse Trust-funded research shows that horses get injured relatively frequently - much more often than you would expect. Interestingly, most of the injuries happen during turnout, rather than during ridden exercise."
The results were obtained through analysing the responses from 652 randomly selected horse owners from north-west England, Midlands and North Wales, all of whom had a horse aged 15 years or younger. Owners sought veterinary treatment for 47% of the injuries reported, while the remainder were treated by the owner or a friend, or required no treatment.
Rosie identified a number of factors that were associated with an increased risk of injury. For example, horses that had been owned for a shorter period of time were found to be significantly more at risk of injury. She says the increased risk may be due to aggression from other horses when a new horse is introduced to a field, but owners can take various steps to reduce the likelihood of injury: "It's worth trying to avoid regular changes in group composition. A new horse should be introduced to the group gradually, preferably by providing adjacent stabling initially. Protective boots may help as the lower limbs are most at risk of injury. Also, if possible, the other horses in the field should have their shoes taken off during the period of adjustment, so they are less able to injure the new horse."
Rosie also found that horses turned out within larger groups were at an increased risk of injury. This is probably due to there being a larger hierarchy with multiple horses competing for dominance. However, she found that the risk of injury reduced when additional feeding areas were provided in the field: "If you provide hay or haylage to horses in the field, it's worth including an additional feeding area to reduce competition for food."
Other interesting findings included the lower incidence of injury in cob and pony breeds, compared to other breeds. Horses used competitively also had a higher risk of injury, which may be due to the additional athletic demands placed on these horses, or due to the way these horses are managed. Horses trained using Parelli methods were also found to be at an increased risk of injury, but as the numbers in this group were small, more research is needed to confirm this.
Although most of the injuries recorded in the survey occurred during turnout, 11% occurred in the stable, with most of the injuries affecting the head or eye. Rosie says owners can easily reduce the risk of stable injury: "There are various simple steps that owners can take to reduce the risk of injury in the stable. Try to provide hay from the floor, instead of in a hay rack, and make sure there are no protruding nails, hooks or sharp edges in the stable."
Rosie said that it would be useful to conduct further research to understand how injuries occur during turnout: "A lot of injuries are reported during turnout, but we're uncertain about what happened. It would be useful to observe the behaviour of horses in the field to see whether it's competition for food, or another factor, that is responsible for the high rate of injuries among horses."
Jeanette Allen, Chief Executive of The Horse Trust, said: "We are pleased that the research we've funded has provided such useful statistics on the risks of injury for horses. We hope that horse owners will follow some of the tips that Rosie has suggested to reduce the risk of their horse being injured."
The Royal College of Veterinary Surgeons is calling for comment on a draft Performance Protocol, which aims to manage proportionately any justified concerns about the professional performance of veterinary surgeons and registered veterinary nurses.
The RCVS's Preliminary Investigation and Advisory Committees have been working together to develop a new protocol setting out the way in which the College will respond to ongoing performance-related concerns. There is an expectation that veterinary surgeons and RVNs are already regularly reviewing their clinical work in the workplace. This will be reinforced by the new principles-based Code of Professional Conduct, currently being finalised, which is likely to require clinical governance to be part of professional practice for veterinary surgeons and RVNs.
According to the College, the draft protocol is intended to formalise and build on the way it already manages ongoing serious performance-related concerns. It introduces new measures, including supervision and undertakings, to seek to ensure that veterinary surgeons and RVNs take reasonable steps to address any serious performance concerns. This will bring the RCVS into line with other professional regulators and enable a tailored and proportionate response to these cases to protect the welfare of animals and the public interest. The College's current system of offering advice to veterinary surgeons and RVNs will remain for complaints which are closed, because there is no indication of serious professional misconduct.
The College says that according to independent legal advice, such an approach is appropriate and necessary in order for it to fulfil its regulatory responsibilities. The draft performance protocol follows similar legal advice that supported the implementation of the RCVS Health Protocol, and both protocols clarify the College's parallel jurisdiction relating to health and performance-related issues.
RCVS President Jerry Davies said: "When veterinary surgeons and registered veterinary nurses are unable to deal with performance-related concerns, it is important that we are able to provide a supportive framework to oversee remedial steps that are designed to address those concerns and encourage professional development. This is best achieved outside a Disciplinary Committee hearing, if at all possible".
The approved draft protocol is now open for public consultation, and may be found at www.rcvs.org.uk/performance. All comments on the draft should be emailed to Simon Wiklund, Advisory Manager at s.wiklund@rcvs.org.uk by 13 January 2012, with 'Performance Protocol' added to the subject heading.
The feedback received from the consultation will be considered by the Preliminary Investigation and Advisory Committees in January 2012, before being submitted to RCVS Council for approval in March.
The College says it hopes that a performance protocol will form part of the supporting guidance to the new RCVS Codes of Professional Conduct for both veterinary surgeons and registered veterinary nurses.
The company points to a survey of 1000 dog owners it conducted in July which found that 77% would put many of the top ten signs of Cushing's down to ‘old age’.
According to research carried out by CM research in July 2018, for every 100 cases of Cushing’s syndrome treated, a further 57 are suspected but not diagnosed.
The ‘Prime Suspects’ campaign will encourage dog owners to become a ‘Cushing’s Detective’ and look out for signs in their dogs.
To help, the company has developed a series of characters to illustrate the signs of Cushings: Panting Patsy, Leaky Larry, Lazy Lynn, Greedy Gus and Little Patch.
A nationwide pet-focused multimedia campaign will support the ‘Prime Suspects’ initiative and will include TV and print advertising, online banners, pay per click advertising and social media to engage owners and encourage them to seek advice from their vet if they suspect Cushing’s in their dog.
Dechra has also launched Cushing’s Connect, a digital platform single resource hub to help vets keep up to date with current best practice in managing Cushing’s.
The hub has information and tools to enhance diagnostic protocols, advice and literature covering pathophysiology, diagnosis and ongoing case management including treatment protocols and monitoring schedules, and interactive guides and videos by top veterinary specialists.
There's also a client communication toolkit with owner-focused resources to encourage dog owners to spot the signs and seek help from their vet.
https://www.dechra.co.uk/cushings-connect
The British Veterinary Association has welcomed the European Commission's Action Plan on Antimicrobial resistance (AMR), launched yesterday on the eve of European Antibiotic Awareness Day.
The Action Plan sets out 12 actions:
However, the association has expressed concern that the Commission has given only qualified support for new antimicrobials for veterinary use. Carl Padgett, President of the BVA, said: "There is much to be applauded in this action plan. In particular the BVA supports the calls for more and better coordinated research, more responsible use of antimicrobials in human and veterinary medicine, and the development of diagnostic tools to quickly and accurately identify the right drug for the right bug.
"The use of antimicrobials in the treatment and control of animal diseases is essential and the BVA supports the strong messages in this plan. Any option for managing AMR must be firmly rooted in sound scientific assessment of the risk.
"While the report recognises the difficulties that have led to the hampering of research into new antimicrobials for veterinary use, we are concerned that there is only qualified support from the Commission for the development of these new medicines for animal use.
"Research into new antimicrobials should be supported in both human and veterinary medicine. We need to ensure the creation of a more predictable regulatory environment to encourage new products for animals to be brought to the market.
"Finally, while the BVA supports the need for a new regulatory framework any new regulations must not impede the ability of veterinary surgeons to prescribe and dispense medicines according to their clinical judgement."
Meanwhile, Jill Moss of the Bella Moss Foundation added her voice to those calling for responsible use of antibiotics, highlighting recent research from the Royal Veterinary College that has established a clear link between pets with MRSA infection and human hospital-associated MRSA. What is less widely recognised, she says, is that resistant bacteria can be passed from human to animal.
The charity is now calling on health and veterinary professionals to work together to achieve a reduction in resistant infections by raising awareness and promoting the responsible use of antibiotics.
Vets Now Ltd, the provider of out-of-hours emergency vet care has announced the acquisition of Salus Quality Partnerships (QP), a Health and Safety service provider to the veterinary profession in the UK.
Vets Now says this acquisition will extend the range of its services aimed at improving the quality of life within the profession and supporting practices to run more efficiently.
Vets Now currently runs 50 emergency clinics throughout the country including two referral hospitals in Scotland and the South West of England. In recent years Vets Now has extended its offering to the profession to include business services aimed at supporting vet practices. These services include Lifelearn (Client Education & Compliance), Staff Training Services, RCVS Practice Standards support and Practice Web services.
Salus QP, which has been running for over 18 years, offers veterinary practices information and services to help them comply with Health and Safety legislation and an anaesthetic monitoring service.
Richard Dixon, Founder of Vets Now said: "Our core purpose at Vets Now has always been to improve the lives of vets and pets, and the recent addition of Salus QP will help to do exactly that. The Salus QP team, led by Mark Enright and Alison Clark, have extensive knowledge in their field and crucially they fully understand the issues as they specifically apply to veterinary practices. With Salus QP our aim is to keep it simple and practical, helping practices fulfil their obligations without letting the Health and Safety tail wag the practice dog. I am very much looking forward to working with both Mark and Alison in the future as we take a fresh and common sense approach to Health and Safety in our profession."
Mark Enright said: "Salus QP and Vets Now both share a strong commitment to the veterinary profession and I truly believe that together we will be greater than the sum of our parts. I look forward to a future of innovations and benefits for all, and to continue to form quality partnerships within the veterinary profession."
Ceva Animal Health has added a new presentation to its Cardio Academy CPD website, entitled: Echocardiography: Common Views.
In the 30 minute multimedia presentation, cardiology specialist Anne French discusses the most common echocardiographic views used in the diagnosis of the cardiac patient.
Veterinary professionals can then receive a CPD certificate by completing a quiz about the session.
In addition, you can still access the the first five sessions, covering the Pathophysiology of Mitral Valve Disease, by Adrian Boswood, Clinical Examination of the Cardiac Dog, by Gérard Le Bobinnec and three sessions discussing Thoracic X-rays by Nicole Van Israël.
For further information, please contact your local Ceva account manager.
Woodley Equipment has become the UK distributor for the full portfolio of SpotChem products from Japanese manufacturer, Arkray.
The range of products includes:
For more information about the new SpotChem analysers, visit: www.woodleyequipment.com/, email: sales@woodleyequipment.com or call on +44(0)1204 669033.
The NOAH Code of Practice Committee, chaired by Mr Guy Tritton, has found Dechra Veterinary Products in breach of three items of the NOAH Code, following a complaint.
The complaint related to an advertisement and detailer promoting Felimazole with the wording "Are you taking a heavy-handed approach to hyperthyroidism?" and "with Felimazole, you don't have to!"
The Committee took the view that by implication this referred to Vidalta because Vidalta is the only other licensed oral treatment on the market for hyperthyroidism.
As a result, the Committee found both promotions in breach of Clause 4.3 because of the implication that Vidalta is less safe than Felimazole.
The Committee did not consider the promotions disparaged the manufacturer as there is no evidence to show it is unsafe.
The Committee also found that the table in the detailer (page 4) suggesting that one dosage of 5 mg per day of Felimazole has the same efficacy as two doses of 2.5 mg, (which is contrary to the dosing statement within the SPC: "If, for reasons of compliance, once daily dosing with a 5 mg tablet is preferable, then this is acceptable although reduced efficacy can be expected compared to a twice daily regime.") was misleading, contrary to Clause 4.3 of the Code.
Full details of the Committee's rulings are on the NOAH website at www.noah.co.uk/code. The full report of this particular case will be available shortly.
Robexera is a COX2 NSAID formulation which delivers anti-inflammatory pain relief with a once-a-day dosing regime2,3,4.
The product is presented as a flavoured chewable tablet for easier administration by pet owners.
For simplicity when dispensing, it comes in four strengths with colour coded boxes, perforated blisters and a set of PIL sheets that convert to prescribing envelopes in each pack.
Charlotte Read, Krka’s UK Key Account Manager, said: “Delivering reliable, cost-effective perioperative pain relief for soft tissue surgery is an everyday concern for veterinary practices, while OA is the most common cause of chronic pain in dogs5.
"This is why we’re particularly pleased to announce the first generic robenacoxib, Robexera.
“Bioequivalent to the originator product6, Robexera provides fast-acting and targeted pain relief, giving enhanced value to veterinary practices and enabling them to offer their clients improved affordability, particularly for those whose animals are on long term pain-management programmes or have other health issues.”
Viktor Kozjan, General Manager Krka UK, added: “The launch of Robexera is further confirmation of Krka’s commitment to develop solutions that are tried and trusted but also flexible and affordable for our customers and their clients.”
Robexera is now available to order from all national UK veterinary wholesalers.
References